NCT07457541Active, not recruitingPhase 1
Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI
SPECT/CT Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI ([99mTc]Tc- HYNIC-FAPI) in Metastatic Cancer Patients
Source: ClinicalTrials.gov · Last updated 25 Jun 2026
Brief summary (registry, in English)
The study should evaluate the biological distribution of 99mTc-HYNIC-FAPI in metastatic cancer patients.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 3 Mar 2026
- Start date
- 26 Feb 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
- Diseases
- Lung cancer, Pancreatic cancer, Colorectal cancer
- NCT number
- NCT07457541
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 15
- From 26 Feb 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening)
- Ongoing toxicity \> grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's
Other illness
- Active current autoimmune disease or history of autoimmune disease
- Known HIV positive or chronically active hepatitis B or C
Other
- Administration of other investigational medicinal product within 30 days of screening
Who the study is looking for
- Subject is \> 18 years of age
- Clinical and radiological diagnosis of metastatic cancer with histological verification.
- White blood cell count: \> 2.0 x 10\^9/L
- Haemoglobin: \> 80 g/L
- Platelets: \> 50.0 x 10\^9/L
- Bilirubin =\< 2.0 times Upper Limit of Normal
- Serum creatinine: Within Normal Limits
- Blood glucose level not more than 5.9 mmol/L
- A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination
- Subject is capable to undergo the diagnostic investigations to be performed in the study
- Informed consent
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tomsk National Research Medical Center of the Russian Academy of Sciences Coordinator of this site? Confirm its status | Tomsk | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.